GHK-Cus anti-inflammatory profile makes it particularly relevant to researchers studying longevity and systemic health
The latest results from the 2023 TEXAIS trial indicated that the use of exenatide (5 g, twice daily injections for 5 days) did not significantly reduce neurological damage within 7 days in patients with acute ischemic stroke (trial registration numbers: ACTRN12617000409370 and NCT03287076)
How to Reconstitute GHK-Cu GHK-Cu (copper peptide) arrives as a lyophilized powder and needs to be mixed with bacteriostatic water before injection
Saffron contributes to emotional balance
Efficacy and Safety of Liraglutide Versus Sitagliptin, Both in Combination With Metformin, in Chinese Patients With Type 2 Diabetes: A 26-Week, Open-Label, Randomized, Active Comparator Clinical Trial
Nanoencapsulation for drug delivery